Leptin antagonism inhibits prostate cancer xenograft growth and progression
Lisa K Philp, Anja Rockstroh, Martin C Sadowski, Atefeh Taherian Fard, Melanie Lehman, Gregor Tevz, Michelle S Liberio, Charles L Bidgood, Jennifer H Gunter, Stephen McPherson, Nenad Bartonicek, John D Wade, Laszlo Otvos, Colleen C Nelson
ENDOCRINE-RELATED CANCER | BIOSCIENTIFICA LTD | Published : 2021
Hyperleptinaemia is a well-established therapeutic side effect of drugs inhibiting the androgen axis in prostate cancer (PCa), including main stay androgen deprivation therapy (ADT) and androgen targeted therapies (ATT). Given significant crossover between the adipokine hormone signalling of leptin and multiple cancer-promoting hallmark pathways, including growth, proliferation, migration, angiogenesis, metabolism and inflammation, targeting the leptin axis is therapeutically appealing, especially in advanced PCa where current therapies fail to be curative. In this study, we uncover leptin as a novel universal target in PCa and are the first to highlight increased intratumoural leptin and le..View full abstract
This work is supported by the Australian Government Department of Health; and the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award (L K P, A R, M L L, N B, C C N) and the Princess Alexandra Hospital Research Foundation 'It's a Blokes Thing' grant. The Translational Research Institute is supported by a grant from the Australian Government. J D W is an NHMRC Principal Research Fellow (APP1117483). Research at The Florey Institute of Neuroscience and Mental Health is supported by the Victorian Government Operational Infrastructure Support Program.